Migraine and Patent Foramen Ovale (PFO)

Deep Dive

From a western clinical perspective, migraine and patent foramen ovale (PFO) intersect at the level of vascular biology and intracardiac shuntin... From a western clinical perspective, migraine and patent foramen ovale (PFO) intersect at the level of vascular biology and intracardiac shunting. Migraine affects roughly one in seven people, with aura present in about a third. A PFO persists in a quarter of adults. Meta-analyses indicate that PFO is more common among those with migraine with aura than in controls, with odds ratios in the two-to-three range. The leading mechanistic hypothesis is that right-to-left shunting enables microemboli or vasoactive amines to bypass pulmonary filtration, reach the cerebral circulation, and trigger cortical spreading depolarization—the electrophysiologic event underlying aura. Associations appear stronger with larger shunts and atrial septal aneurysm, which increase the probability of paradoxical passage. Whether closing the PFO improves migraine has been tested in randomized trials. The MIST, PRIMA, and PREMIUM trials—designed to evaluate migraine outcomes—did not meet their primary endpoints across unselected migraine populations, tempering early enthusiasm. Nonetheless, some signals emerged: patients with frequent aura and large shunts experienced reductions in aura days or attack frequency in secondary or post hoc analyses. Separately, stroke-prevention trials (RESPECT, CLOSE, REDUCE) established that PFO closure reduces recurrent cryptogenic stroke in carefully selected patients; several reported fewer or less severe migraines as exploratory outcomes after closure. Clinically, this evidence translates into a cautious approach. Current neurology and cardiology guidelines endorse PFO closure for secondary stroke prevention in adults 18–60 years with cryptogenic stroke and high-risk PFO anatomy, but not for migraine alone. Diagnostic evaluation of PFO uses contrast echocardiography (TTE/TEE) or transcranial Doppler, each with trade-offs in sensitivity, invasiveness, and anatomic detail. For most patients, evidence-based migraine care—acute and preventive medications, trigger management, and comorbidity control—remains first-line. Antiplatelet therapy is standard for many PFO patients not undergoing closure; any migraine benefit is uncertain. Shared decision-making should weigh aura phenotype, shunt size, prior embolic events, procedural risks (notably early atrial fibrillation), and patient preferences while acknowledging research gaps.